title: Comparative arterial antithrombotic activity of clopidogrel and acetyl salicylic acid in the pig.
abstract: We investigated the comparative antithrombotic properties of clopidogrel, an analogue of ticlopidine, and aspirin, using the Folts' model on femoral arteries in 22 pigs. On each animal, clopidogrel or aspirin were used to treat the thrombotic process on the left femoral artery and to prevent this process on the right femoral artery. Sequentially: an injury and stenosis were carried out on the left femoral artery; the thrombotic process was monitored with a Doppler during a 30-min observation period for cyclic flow reductions or permanent cessation of flow; after the first cyclic flow reduction occurred, clopidogrel (5 mg kg-1) or aspirin (2.5, 5, 100 mg kg-1) were injected intravenously; if cyclic flow reductions were abolished, epinephrine (0.4 micrograms kg-1 min-1) was injected to try to restore cyclic flow reductions and/or permanent cessation of flow; then injury and stenosis were applied on the right femoral artery. Before and after injection of clopidogrel or aspirin, ear immersion bleeding times and ex-vivo platelet aggregation were performed. Clopidogrel (n = 7) abolished cyclic flow reductions were efficiently prevented, even for two injuries. Basal bleeding time (5 min 28) was lengthened (> 15 min, 30 min after clopidogrel and remained prolonged even after 24 h). ADP-induced platelet aggregation was inhibited (more than 78%). Comparatively, aspirin had a moderate and no dose-dependent effect. Aspirin 2.5 mg kg-1 (n = 6) abolished cyclic flow reductions in 2 animals, CFR reoccurred spontaneously in one animal and epinephrine restored it in a second animal.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department d'Anesthésie, Hôpital Pitié, Paris, France.
authors.forename: C M
authors.initials: CM
authors.lastname: Samama
authors.forename: P
authors.initials: P
authors.lastname: Bonnin
authors.forename: M
authors.initials: M
authors.lastname: Bonneau
authors.forename: G
authors.initials: G
authors.lastname: Pignaud
authors.forename: E
authors.initials: E
authors.lastname: Mazoyer
authors.forename: O
authors.initials: O
authors.lastname: Bailliart
authors.forename: J P
authors.initials: JP
authors.lastname: Maffrand
authors.forename: P
authors.initials: P
authors.lastname: Viars
authors.forename: J P
authors.initials: JP
authors.lastname: Caen
authors.forename: L O
authors.initials: LO
authors.lastname: Drouet
mesh_terms: D000818:Animals; D001241:Aspirin / Q000494:pharmacology*; D001760:Bleeding Time; D000077144:Clopidogrel; D004195:Disease Models, Animal; D005260:Female; D005263:Femoral Artery; D005343:Fibrinolytic Agents / Q000494:pharmacology; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D013552:Swine; D013927:Thrombosis / Q000097:blood / Q000188:drug therapy* / Q000517:prevention & control; D013988:Ticlopidine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D005343:Fibrinolytic Agents; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin